Data from our previous funding period and supporting evidence from other INIA-Neuroimmune (INIA-N) laboratories provide the foundation for the overall hypothesis of this proposal: Behavioral changes characteristic of excessive alcohol consumption and alcohol use disorder (AUD) are due, in part, to neuroimmune mechanisms that significantly reshape the transcriptome. Drug repurposing algorithms can analyze cross-species transcriptome changes to predict compounds that reduce alcohol consumption. We propose that brain dysfunction in alcoholics is the result of dysregulation in both the protein coding and non-coding transcriptome. Advances in genomic studies by our research team and INIA-N collaborators have enabled us to generate transcriptome data on an unprecedented scale. Devising methods to visualize and analyze these data to produce meaningful biological interpretation is one of the next important steps.
We aim to take full advantage of the emerging technologies, allowing us to move forward in the post- genomic, ?big data? era. We previously used RNA sequencing (RNA-Seq) to define the transcriptome in four brain regions of 90 human cases (alcoholics and matched controls). In addition to identifying novel splice variants and co-variation with lifetime alcohol consumption, we identified novel changes in long non-coding RNAs (lncRNAs) in human brain and propose that these play an important role in gene expression changes. Differentially expressed lncRNAs that are correlated with alcohol consumption and have syntenic conservation between humans and mice will be prioritized for genetic and behavioral testing in mice in collaboration with INIA-N investigators. Other interactions involve mining the RNA-Seq transcriptome profiles in human subjects and macaque to link expression changes with genetic differences found in the Collaborative Studies on Genetics of Alcoholism (COGA). This will allow us to define, in unprecedented detail, changes in RNA splicing and pathways constructed from detected single-nucleotide polymorphisms. Finally, we will study the convergence of transcriptome changes in human, macaque, and rodent brain to determine which rodent models reflect the gene expression changes seen in human AUD. The overlapping changes in expression and associated networks produced by excessive alcohol consumption can be used to predict drugs that will normalize the network using cutting-edge computational analyses. Thus, we and INIA-N collaborators will utilize our combined transcriptome data to predict novel therapeutics based on cross-species convergence of gene networks and then test FDA-approved drugs predicted to target the affected networks in mouse and rat models of excessive alcohol consumption. The most promising drugs will then be selected for testing in human alcoholics. These efforts integrate advanced computational, genomic, molecular, functional system, and behavioral studies to be integrated into a systematic framework designed to advance treatment strategies for AUD.

Public Health Relevance

We propose that alcohol-induced changes in brain function are due to alterations in gene expression. Together with other INIA-Neuroimmune investigators, we will explore these expression changes in different species using several innovative approaches, including next-generation sequencing, study of long non-coding RNAs, and bioinformatic strategies, to identify potential treatment options for excessive alcohol drinking from existing FDA-approved drugs. This work will focus on neuroimmune-related genes and drug candidates and will provide new strategies and guidelines for gene-based diagnosis and treatment of alcohol use disorder.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01AA020926-06
Application #
9241777
Study Section
Special Emphasis Panel (ZAA1-CC (02))
Program Officer
Parsian, Abbas
Project Start
2011-09-05
Project End
2022-01-31
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
6
Fiscal Year
2017
Total Cost
$445,995
Indirect Cost
$154,854
Name
University of Texas Austin
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
170230239
City
Austin
State
TX
Country
United States
Zip Code
78712
Ponomarev, Igor; Stelly, Claire E; Morikawa, Hitoshi et al. (2017) Mechanistic insights into epigenetic modulation of ethanol consumption. Alcohol 60:95-101
Kamran, M; Long, Z-J; Xu, D et al. (2017) Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis. Oncogenesis 6:e298
Harris, R Adron; Bajo, Michal; Bell, Richard L et al. (2017) Genetic and Pharmacologic Manipulation of TLR4 Has Minimal Impact on Ethanol Consumption in Rodents. J Neurosci 37:1139-1155
Mayfield, R Dayne (2017) Emerging roles for ncRNAs in alcohol use disorders. Alcohol 60:31-39
Warden, Anna S; Mayfield, R Dayne (2017) Gene expression profiling in the human alcoholic brain. Neuropharmacology 122:161-174
Most, Dana; Leiter, Courtney; Blednov, Yuri A et al. (2016) Synaptic microRNAs Coordinately Regulate Synaptic mRNAs: Perturbation by Chronic Alcohol Consumption. Neuropsychopharmacology 41:538-48
Mayfield, J; Arends, M A; Harris, R A et al. (2016) Genes and Alcohol Consumption: Studies with Mutant Mice. Int Rev Neurobiol 126:293-355
Warden, Anna; Erickson, Emma; Robinson, Gizelle et al. (2016) The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies. Pharmacogenomics 17:2081-2096
Wang, Le-Xun; Wang, Jun-Dan; Chen, Jia-Jie et al. (2016) Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation. Sci Rep 6:35533
Most, D; Ferguson, L; Blednov, Y et al. (2015) The synaptoneurosome transcriptome: a model for profiling the emolecular effects of alcohol. Pharmacogenomics J 15:177-88

Showing the most recent 10 out of 23 publications